

Parkinson's Disease Expertise

- MDs with clinical expertise
- PhD scientists with expertise for image acquisition and analysis
- Key clinical and academic advisors for PD imaging


Neuroimaging Modalities

- SPECT and PET
 - DaTscan (¹²³I-FP-CIT)
 - Dopascan (¹²³I-beta-CIT)
 - ¹⁸F-fluoro-L-DOPA (FDOPA)
 - ¹⁸F-6-fluoro-L-m-tyrosine (FMT)
 - Novel radiotracer support and management
- MRI
 - Eligibility assessment
 - Safety monitoring
 - Volumetric MRI
 - Functional MRI (fMRI)
 - Diffusion Tensor Imaging (DTI)
 - Tractography

Clinical and research applications of functional neuroimaging to Parkinson's disease (PD) and other parkinsonian disorders have advanced over the past decade, leading to novel diagnostic methods and contributing to the development of new therapies. Functional MRI (fMRI), PET, and SPECT are increasingly being used to study the molecular processes underlying PD symptoms, to detect subclinical and early disease, and to monitor disease progression.

Quantitative Analysis

- Striatal Binding Ratio (SBR) and SUVR approaches
- Kinetic analysis (Patlak and other approaches)
- Freesurfer and template-based ROI methods




MRI/SPECT




DaTscan Analysis

High Quality Data - Validated QC Workflows

- Qualification, image acquisition, and data analysis modeled after the Parkinson's Progression Markers Initiative (PPMI)
- Visual checks
 - Adequate counts
 - Artifacts
 - Uptake patterns
 - Correction measures
- Qualification of SPECT/PET centers
 - Phantom scans
 - Protocol validation and adherence
 - Tracer dose/timing



DaTscan



FMT-PET

With 30+ years of experience across hundreds of neurodegenerative disease clinical trials, Bioclinica delivers proven neuroimaging science and operational expertise to advance your neuroscience drug program.